Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia

A trapping defect of fatty acids due to impaired function of acylation-stimulating protein (ASP) has been suggested as one mechanism underlying the metabolic abnormalities in familial combined hyperlipidemia (FCHL). The study aimed at defining the role of ASP and complement C3 in 35 Finnish FCHL families. There was no difference in plasma ASP levels between the 66 hypertriglyceridemic FCHL patients and their 84 normotriglyceridemic relatives. No response in plasma ASP could be observed after a fatty meal in 10 FCHL patients or in 10 control subjects. In familial correlation analyses, C3 exhibited a significant sibling-sibling correlation. The FCHL patients had higher serum C3 levels than their unaffected relatives (P <0.001). Furthermore, serum C3 levels correlated significantly with several lipid parameters. The correlations between ASP and lipid variables were weaker than those of C3. These analyses suggest that common genes might contribute to the regulation of serum C3, triglycerides, HDL-C, free fatty acids, and insulin. The present data do not support the hypothesis that defects of the ASP pathway are reflected in plasma lipoproteins or in impaired plasma lipid clearance postprandially.

[1]  R. Pratley,et al.  Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. , 2000, Diabetes care.

[2]  K. Cianflone,et al.  Of mice and men (and women) and the acylation-stimulating protein pathway. , 2000, Current opinion in lipidology.

[3]  R. Pratley,et al.  Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. , 1999, Obesity research.

[4]  H. Rus,et al.  Complement activation and atherosclerosis. , 1999, Molecular immunology.

[5]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[6]  L. Chan,et al.  Genetic Deficiency of Acylation Stimulating Protein (ASP(C3ades-Arg)) Does Not Cause Hyperapobetalipoproteinemia in Mice* , 1999, The Journal of Biological Chemistry.

[7]  L. Campbell,et al.  The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers , 1998, International Journal of Obesity.

[8]  M. Laakso,et al.  Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Sniderman,et al.  Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB , 1998, European journal of clinical investigation.

[10]  K. Cianflone,et al.  Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. , 1998, Journal of lipid research.

[11]  K. Cianflone,et al.  The adipocyte, fatty acid trapping, and atherogenesis. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[12]  T. Lehtimäki,et al.  Phenotype expression in familial combined hyperlipidemia. , 1997, Atherosclerosis.

[13]  K. Cianflone,et al.  Plasma acylation-stimulating protein in coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Aitman,et al.  Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  L. Peltonen,et al.  Serum complement and familial combined hyperlipidemia. , 1997, Atherosclerosis.

[16]  J. Björkegren,et al.  Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Hamsten,et al.  Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. , 1994, Journal of lipid research.

[18]  J Ludbrook,et al.  Repeated measurements and multiple comparisons in cardiovascular research. , 1994, Cardiovascular research.

[19]  K. Cianflone,et al.  The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. , 1993, The Journal of clinical investigation.

[20]  K. Cianflone,et al.  Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. , 1993, Metabolism: clinical and experimental.

[21]  B. Spiegelman,et al.  Adipsin and an endogenous pathway of complement from adipose cells. , 1992, The Journal of biological chemistry.

[22]  Richard H. Myers,et al.  Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.

[23]  S Senn,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.

[24]  K. Cianflone,et al.  Impaired response of fibroblasts from patients with hyperapobetalipoproteinemia to acylation-stimulating protein. , 1990, The Journal of clinical investigation.

[25]  K. Cianflone,et al.  Metabolic response of Acylation Stimulating Protein to an oral fat load. , 1989, Journal of lipid research.

[26]  K. Cianflone,et al.  Purification and characterization of acylation stimulating protein. , 1989, The Journal of biological chemistry.

[27]  M. Taskinen,et al.  Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes , 1988, Arteriosclerosis.

[28]  A. Sniderman,et al.  Adipose tissue glyceride synthesis in patients with hyperapobetalipoproteinemia. , 1988, Canadian journal of physiology and pharmacology.

[29]  M. Cucuianu,et al.  Increased level of the complement C3 protein in endogenous hypertriglyceridemia. , 1982, Journal of clinical & laboratory immunology.

[30]  P. Puddu,et al.  Relationship between serum C3 levels and traditional risk factors for myocardial infarction. , 1998, Acta cardiologica.

[31]  H. Colten,et al.  Complement C3 deficiency: human, animal, and experimental models. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.

[32]  M. Miller,et al.  The effect of three serum basic proteins on the mass of lipids in normal and hyperapoB fibroblasts. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  S. Grundy,et al.  Familial combined hyperlipidemia workshop , 1989 .